Cytotoxic T-lymphocyte-associate antigen 4
(Redirected from Ipilimumab)
Jump to navigation
Jump to search
Cytotoxic T-lymphocyte-associate antigen 4, abbreviated CTLA-4, is a receptor on the T cell that down regulates immune function.
Antibodies directed at CTLA-4 are used to treat melanoma.
Drugs
- Ipilimumab.
- Tremelimumab.
Background
Cytotoxic T cell activation is driven by three sets of receptors:[1]
| Pairings | Dentritic cell | T cell |
|---|---|---|
| Antigen presenting | MHC | TCR |
| Activation signal | B7 | CD28 |
| Inhibitory signal | B7 | CTLA-4 |
See also
References
- ↑ Ribas, A. (Jun 2012). "Tumor immunotherapy directed at PD-1.". N Engl J Med 366 (26): 2517-9. doi:10.1056/NEJMe1205943. PMID 22658126.